Frontiers in Pharmacology (Aug 2022)

Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents

  • Yang Li,
  • Qing Lu,
  • Chenghu Xie,
  • Yiming Yu,
  • Ao Zhang,
  • Ao Zhang

DOI
https://doi.org/10.3389/fphar.2022.956220
Journal volume & issue
Vol. 13

Abstract

Read online

The p21-activated kinase 4 (PAK4) is a member of the PAKs family. It is overexpressed in multiple tumor tissues. Pharmacological inhibition of PAK4 attenuates proliferation, migration, and invasion of cancer cells. Recent studies revealed that inhibition of PAK4 sensitizes immunotherapy which has been extensively exploited as a new strategy to treat cancer. In the past few years, a large number of PAK4 inhibitors have been reported. Of note, the allosteric inhibitor KPT-9274 has been tested in phase Ⅰ clinic trials. Herein, we provide an update on recent research progress on the PAK4 mediated signaling pathway and highlight the development of the PAK4 small molecular inhibitors in recent 5 years. Meanwhile, challenges, limitations, and future developmental directions will be discussed as well.

Keywords